The consequences of failure to achieve targets of guidelines for prevention and treatment of diabetic complications in patients with type 1 diabetes

Acta Diabetologica

Volumn 52, Issue 1, 2015, Pages 31-38

  Lithovius, Raija ^a,b   Harjutsalo, Valma ^a,b,c   Forsblom, Carol ^a,b   Saraheimo, Markku ^a,b   Groop, Per Henrik ^a,b,d  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^d BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

All cause mortality; Cardiovascular disease; Diabetic nephropathy; Guidelines; Type 1 diabetes

Indexed keywords

GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CLINICAL TRIAL; COHORT ANALYSIS; COMPLICATION; DIABETES MELLITUS, TYPE 1; FINLAND; GLUCOSE BLOOD LEVEL; HUMAN; MALE; MEDICAL SOCIETY; METABOLISM; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; RISK FACTOR; UNITED STATES; YOUNG ADULT;

ADULT; AGED; AMERICAN MEDICAL ASSOCIATION; BLOOD GLUCOSE; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; COHORT STUDIES; DIABETES MELLITUS, TYPE 1; FINLAND; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS; UNITED STATES; YOUNG ADULT;

EID: 84939898433     PISSN: 09405429     EISSN: 14325233     Source Type: Journal    
DOI: 10.1007/s00592-014-0595-x     Document Type: Article

References (32)

1. Nathan DM (1993) Long-term complications of diabetes mellitus. N Engl J Med 328:1676–1685
2. American Diabetes Association (2008) Economic costs of diabetes in the US in 2007. Diabetes Care 31:596–615
3. American Diabetes Association (2013) Standards of medical care in diabetes—2013. Diabetes Care 36:S11–S66
4. The Diabetes Control and Complications Trial Research Group (DCCT) (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977–986
5. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group, Nathan DM, Zinman B, Cleary PA et al (2009) Modern-day clinical course of type 1 diabetes mellitus after 30 years’ duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983–2005). Arch Intern Med 169:1307–1316
6. UK prospective diabetes study (UKPDS) group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 352:837–853
7. ACCORD Study Group, Cushman WC, Evans GW, Byington RP (2010) Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 362:1575–1585
8. Laing SP, Swerdlow AJ, Slater SD et al (2003) Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes. Diabetologia 46:760–765
9. Soedamah-Muthu SS, Chaturvedi N, Witte DR et al (2008) Relationship between risk factors and mortality in type 1 diabetic patients in Europe: the EURODIAB Prospective Complications Study (PCS). Diabetes Care 31:1360–1366
10. Harjutsalo V, Forsblom C, Groop PH (2011) Time trends in mortality in patients with type 1 diabetes: nationwide population based cohort study. BMJ 343:d5364
11. Livingstone SJ, Looker HC, Hothersall EJ et al (2012) Risk of cardiovascular disease and total mortality in adults with type 1 diabetes: Scottish registry linkage study. PLoS Med 9:e1001321
12. Harjutsalo V, Maric-Bilkan C, Forsblom C, Groop PH (2014) Impact of sex and age at onset of diabetes on mortality from ischemic heart disease in patients with type 1 diabetes. Diabetes Care 37:144–148
13. Bryant W, Greenfield JR, Chisholm DJ, Campbell LV (2006) Diabetes guidelines: easier to preach than to practice? Med J Aust 185:305–309
14. Resnick HE, Foster GL, Bardsley J, Ratner RE (2006) Achievement of American Diabetes Association clinical practice recommendations among US adults with diabetes, 1999–2002: the National Health and Nutrition Examination Survey. Diabetes Care 29:531–537
15. Ali MK, Bullard KM, Saaddine JB, Cowie CC, Imperatore G, Gregg EW (2013) Achievement of goals in US diabetes care, 1999–2010. N Engl J Med 368:1613–1624
16. Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499–502
17. Levey AS, Stevens LA, Schmid CH et al (2009) CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med 150:604–612
18. Williams KV, Erbey JR, Becker D, Arslanian S, Orchard TJ (2000) Can clinical factors estimate insulin resistance in type 1 diabetes? Diabetes 49:626–632
19. DeGuzman PB, Akosah KO, Simpson AG et al (2012) Sub-optimal achievement of guideline-derived lipid goals in management of diabetes patients with atherosclerotic cardiovascular disease, despite high use of evidence-based therapies. Diabetes Vasc Dis Res 9:138–145
20. Cheung BM, Ong KL, Cherny SS, Sham PC, Tso AW, Lam KS (2006) Diabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006. Am J Med 122:443–453
21. Maahs DM, Kinney GL, Wadwa P et al (2005) Hypertension prevalence, awareness, treatment, and control in an adult type 1 diabetes population and a comparable general population. Diabetes Care 28:301–306
22. Beaton SJ, Nag SS, Gunter MJ, Gleeson JM, Sajjan SS, Alexander CM (2004) Adequacy of glycemic, lipid, and blood pressure management for patients with diabetes in a managed care setting. Diabetes Care 27:694–698
23. Arauz-Pacheco C, Parrott MA, Raskin P (2002) The treatment of hypertension in adult patients with diabetes. Diabetes Care 25:134–147
24. Hovind P, Rossing P, Tarnow L, Smidt UM, Parving HH (2001) Remission and regression in the nephropathy of type 1 diabetes when blood pressure is controlled aggressively. Kidney Int 60:277–283
25. Bjorck S, Nyberg G, Mulec H, Granerus G, Herlitz H, Aurell M (1986) Beneficial effects of angiotensin converting enzyme inhibition on renal function in patients with diabetic nephropathy. Br Med J (Clin Res Ed) 293:471–474
26. Fagard RH (2012) Resistant hypertension. Heart 98:254–261
27. Calhoun DA, Jones D, Textor S, Goff DC et al (2008) Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association professional education committee of the council for high blood pressure research. Hypertension 51:1403–1419
28. Persell SD (2011) Prevalence of resistant hypertension in the United States, 2003–2008. Hypertension 57:1076–1080
29. De Nicola L, Gabbai FB, Agarwal R et al (2013) Prevalence and prognostic role of resistant hypertension in chronic kidney disease patients. J Am Coll Cardiol 61:2461–2467
30. Lithovius R, Harjutsalo V, Forsblom C, Saraheimo M, Groop PH, On behalf of the FinnDiane Study Group (2014) Antihypertensive treatment and resistant hypertension in patients with type 1 diabetes by stages of diabetic nephropathy. Diabetes Care 37:709–717
31. Valle T (2010) [Glycaemic control in patients with diabetes in Finland in 2009–2010]. DEHKO-report 2010: 5. Finnish Diabetes Association 2010. Finnish
32. Waden J, Forsblom C, Thorn LM, Gordin D, Saraheimo M, Groop PH, Finnish Diabetic Nephropathy Study Group (2009) A1C variability predicts incident cardiovascular events, microalbuminuria, and overt diabetic nephropathy in patients with type 1 diabetes. Diabetes 58:2649–2655